Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 60 weeks for participants not transitioning into the long-term extension (LTE) study and will be up to approximately 52 weeks for participants transitioning into the LTE study. The randomized treatment duration will be up to approximately 48 weeks.

NCT Number	NCT07170917
Lead Sponsor	Sanofi
Conditions	Hidradenitis Suppurativa
Enrollment	208 participants
Start Date	2025-11-06
Primary Completion	2027-08-01 (estimated)
Study Completion	2028-04-27 (estimated)
Updated on ClinicalTrials.gov	2026-06-12